The latest report by IMARC Group, titled “Australia Medical Cannabis Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033,” offers a comprehensive analysis of the Australia medical cannabis market growth. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry. The Australia medical cannabis market size reached USD 740.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,373.1 Million by 2033, exhibiting a growth rate (CAGR) of 7.10% during 2025–2033.
Report Attributes:
- Base Year: 2024
- Forecast Years: 2025–2033
- Historical Years: 2019–2024
- Market Size in 2024: USD 740.0 Million
- Market Forecast in 2033: USD 1,373.1 Million
- Market Growth Rate 2025–2033: 7.10%
For an in-depth analysis, you can refer to a sample copy of the report:
https://www.imarcgroup.com/australia-medical-cannabis-market/requestsample
Australia Medical Cannabis Market Overview
- More government approvals are happening, which helps patients get medical cannabis more easily.
- Doctors are becoming more open to using cannabis and are aware of its health benefits, so they are writing more prescriptions.
- More people are suffering from long-term health issues like pain and PTSD, which is driving the need for cannabis-based treatments.
- Growing domestic growing and investment are helping reduce the need to bring in cannabis from other countries.
- Telehealth clinics are changing how people get care by offering online doctor visits and prescriptions.
- New types of cannabis products, such as high-THC flowers, oils, capsules, and creams, are giving patients more choices for their treatment.
Key Features and Trends of Australia Medical Cannabis Market
- Pharmaceutical-grade GMP standards are helping to ensure safety and consistent dosing.
- Dried flower and vaporized products are becoming more popular for quick relief.
- Working with global cannabis brands is increasing the range of options for patients.
- Support from states and clear rules are helping the business grow in different regions.
- Using digital health tools is making it easier to sign up patients and provide ongoing care.
Growth Drivers of Australia Medical Cannabis Market
- More people are dealing with long-term health issues that aren’t being properly treated with standard medicines.
- There is growing support from TGA and changing rules that help new treatments get approved and used.
- More doctors are allowed to prescribe, and telehealth services are making it easier for patients to get care.
- Doctors and patients are becoming more confident because there is solid research and clear guidelines in place.
- General practitioners are getting more involved because of better training and efforts by patient groups.
Innovation & Market Demand of Australia Medical Cannabis Market
- Clinics and brands are developing rapid-release formulations for chronic pain and anxiety.
- Technology-driven patient monitoring solutions are supporting long-term therapy management.
- Cross-border product development is introducing global standards and product quality.
- Data-driven insights are refining dosing regimens for individual patient needs.
- Collaborative research between universities and industry is identifying new indications.
Australia Medical Cannabis Market Opportunities
- Expansion of cannabis treatment to new conditions such as autism and neurodegenerative diseases.
- Market entry potential for international pharmaceutical and biotech firms.
- Growth in export opportunities for Australian GMP-certified products.
- Improved reimbursement prospects as clinical data strengthens efficacy claims.
- Strategic investments in local cultivation and technology platforms are driving market scale.
Australia Medical Cannabis Market Challenges
- Regulatory variations across states are complicating prescribing and distribution.
- Price pressures persist as more generics and imports enter the market.
- Physician hesitancy and lack of comprehensive patient education can limit uptake.
- Supply chain disruptions may intermittently affect product availability.
- Stigmatization and insurance limitations continue to restrict access for some patients.
Australia Medical Cannabis Market Analysis
- Market is seeing a shift from predominantly CBD products to balanced and THC-rich formats.
- Greater integration with mainstream healthcare, especially in palliative and pain settings.
- Consolidation among licensed producers is increasing operational efficiency.
- Increased real-world evidence is informing policy and clinical decision-making.
- Growing number of clinical trials is validating cannabis across more indications.
Australia Medical Cannabis Market Segmentation:
- By Species:
- Indica
- Sativa
- Hybrid
- By Derivative:
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
- By Application:
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
- By Route of Administration:
- Oral Solutions and Capsules
- Vaporizers
- Topicals
- Others
- By End Use:
- Pharmaceutical Industry
- Research and Development Centers
- Others
- By Region:
- Australia Capital Territory & New South Wales
- Victoria & Tasmania
- Queensland
- Northern Territory & Southern Australia
- Western Australia
Australia Medical Cannabis Market News & Recent Developments:
- In September 2024, Tilray Medical introduced Redecan EU-GMP medical cannabis products in Australia, enhancing patient and physician choice.
- In February 2025, Dispensed announced expansion into New Zealand, further accelerating regional market growth.
Australia Medical Cannabis Market Key Players:
- Tilray Medical
- Cann Group
- Althea Group Holdings
- Medlab Clinical
- Little Green Pharma
- AusCann Group
- Bod Australia
Key Highlights of the Report:
- Market Performance (2019–2024)
- Market Outlook (2025–2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Ask analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=32011&flag=E
🔍 FAQs: Australia Medical Cannabis Market
Q1: What is the projected CAGR of Australia’s medical cannabis market?
A: The market is expected to grow at a CAGR of 7.10% during 2025–2033.
Q2: Which regions are leading in medical cannabis adoption?
A: Australia Capital Territory & New South Wales, and Victoria & Tasmania are among the leading regions.
Q3: What formats are most in demand for medical cannabis in Australia?
A: Dried flower (especially high-THC), oils, capsules, and topicals currently have the strongest demand.
Q4: What are the regulatory pathways for medical cannabis prescriptions?
A: Prescriptions are authorized via the TGA’s Special Access Scheme (SAS) and Authorised Prescriber program.
Q5: How are clinical research and telehealth shaping the market?
A: Ongoing research is validating new indications, and telehealth clinics are expanding rapid patient access.
About Us:
IMARC Group is a leading market research company that provides management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our solutions include comprehensive market intelligence, custom consulting, and actionable insights to help organizations make informed decisions and achieve sustainable growth.
Contact Us:
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-631-791-1145.
